HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Friday,Benzinga reports. The brokerage currently has a $26.00 target price on the stock.
A number of other research firms have also weighed in on ALMS. Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective on the stock. Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.83.
Check Out Our Latest Report on ALMS
Alumis Trading Up 2.2 %
Institutional Trading of Alumis
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC acquired a new stake in shares of Alumis in the 3rd quarter worth approximately $197,000. Geode Capital Management LLC acquired a new stake in Alumis in the third quarter valued at $3,266,000. State Street Corp purchased a new position in shares of Alumis in the third quarter valued at $866,000. Stifel Financial Corp acquired a new position in shares of Alumis during the 3rd quarter worth $931,000. Finally, Samsara BioCapital LLC purchased a new stake in shares of Alumis in the 3rd quarter worth about $34,886,000.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
- Five stocks we like better than Alumis
- What is the Nikkei 225 index?
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- How to Most Effectively Use the MarketBeat Earnings Screener
- CarMax Gets in Gear: Is Now the Time to Buy?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.